DNA methylation in promoter region as biomarkers in prostate cancer.

Methods in Molecular Biology
Mihi Yang, Jong Y Park

Abstract

The prostate gland is the most common site of cancer and the second leading cause of cancer death in American men. Recent emerging molecular biological technologies help us to know that epigenetic alterations such as DNA methylation within the regulatory (promoter) regions of genes are associated with transcriptional silencing in cancer. Promoter hypermethylation of critical pathway genes could be potential biomarkers and therapeutic targets for prostate cancer. In this chapter, we updated current information on methylated genes associated with the development and progression of prostate cancer. Over 40 genes have been investigated for methylation in promoter region in prostate cancer. These methylated genes are involved in critical pathways, such as DNA repair, metabolism, and invasion/metastasis. The role of hypermethylated genes in regulation of critical pathways in prostate cancer is discussed. These findings may provide new information of the pathogenesis, the exciting potential to be predictive and to provide personalized treatment of prostate cancer. Indeed, some epigenetic alterations in prostate tumors are being translated into clinical practice for therapeutic use.

Citations

Sep 7, 2014·BMC Cancer·Nataša VasiljevićAttila T Lorincz
Oct 3, 2014·Journal of Cancer Research and Clinical Oncology·Takamasa TakahashiToshikazu Ushijima
Nov 18, 2014·Biomarkers in Medicine·Nataša VasiljevićAttila T Lorincz
Dec 15, 2016·Nature Communications·Mahya MehrmohamadiJason W Locasale
Nov 10, 2015·The Journal of Urology·Javier C AnguloSantiago Ropero
May 26, 2015·Nature Biotechnology·Hongzhi CaoJun Wang
Nov 22, 2012·Journal of Environmental Science and Health. Part C, Environmental Carcinogenesis & Ecotoxicology Reviews·Minju KimMihi Yang
Feb 11, 2020·Molecular Genetics & Genomic Medicine·Jia Li, Xinzheng Li
Oct 24, 2019·Clinical Epigenetics·Reka TothClarissa Gerhäuser
Jul 12, 2018·International Neurourology Journal·Jong-Myon Bae
Oct 20, 2017·Oncology Reports·Maria Nowacka-Zawisza, Ewelina Wiśnik
Feb 19, 2020·Current Pharmaceutical Design·Majid AssadiHojjat Ahmadzadehfar
Jan 17, 2021·International Journal of Molecular Sciences·Gilberto Ruiz-DeyaJong Y Park
Nov 13, 2021·Experimental and Therapeutic Medicine·Adrian AlbulescuAnca Botezatu

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cell Signaling & Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. This feed covers the latest research on signaling and epigenetics in cell growth and cancer.

Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics and Senescence (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may be involved in regulating senescence in cancer cells. This feed captures the latest research on cancer epigenetics and senescence.

Cancer Epigenetics & Methyl-CpG (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. Here is the latest research on cancer epigenetics and methyl-CpG binding proteins including ZBTB38.

Cancer Epigenetics & Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.

Related Papers

Biochimica Et Biophysica Acta
Long-Cheng LiRajvir Dahiya
Zhonghua nan ke xue = National journal of andrology
Shui-Gen ZhouJian-Ping Gao
© 2022 Meta ULC. All rights reserved